Last 7 days
-0.9%
Last 30 days
-6.7%
Last 90 days
19.9%
Trailing 12 Months
87.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 116.8B | 26.2B | -8.85% | -12.37% | 14.75 | 4.46 | -0.48% | 38.34% |
GILD | 95.3B | 27.0B | -7.15% | 22.78% | 17.06 | 3.52 | -1.56% | 23.65% |
MRNA | 49.5B | 15.1B | -3.01% | -12.71% | 10.35 | 3.29 | -33.37% | -67.32% |
BIIB | 43.1B | 10.1B | -1.82% | 44.85% | 13.78 | 4.27 | -6.61% | 115.98% |
MID-CAP | ||||||||
NBIX | 8.8B | 1.6B | -10.82% | -3.21% | 137.28 | 5.5 | 32.38% | -10.36% |
DNLI | 4.0B | - | 17.83% | 16.01% | -10.8 | 36.9 | 122.90% | -29.67% |
BEAM | 2.4B | 76.7M | 3.87% | -11.56% | -7.51 | 30.96 | 41.73% | -32.75% |
BBIO | 2.2B | 107.9M | -6.75% | 87.02% | -4.48 | 20.12 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 119.0M | 13.50% | 5.58% | -5.31 | 12.45 | -69.61% | -584.39% |
REPL | 1.1B | 10.0M | 10.82% | 23.60% | -6.03 | 105.01 | 215.65% | -47.65% |
NVAX | 641.1M | - | -3.13% | -86.56% | -0.55 | 0.32 | 72.89% | 12.32% |
FATE | 487.0M | 136.9M | -18.29% | -78.97% | -2.07 | 3.56 | 116.83% | -0.93% |
SGMO | 191.0M | 241.0M | -22.11% | -68.89% | -1.5 | 0.79 | 113.96% | 27.87% |
VXRT | 166.8M | 697.0K | 51.20% | -67.02% | -1.55 | 239.29 | 47.98% | -35.48% |
IBIO | 9.0M | - | -32.41% | -88.55% | -0.12 | 3.21 | 0.51% | -129.47% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 9.7% | 108 | 98.00 | 89.00 | 79.00 | 70.00 |
S&GA Expenses | -13.8% | 143 | 166 | 181 | 191 | - |
R&D Expenses | -7.3% | 399 | 431 | 443 | 436 | - |
EBITDA | - | 556 | - | - | - | - |
EBITDA Margin | - | 7.97* | - | - | - | - |
EBT Margin | - | 7.25* | - | - | - | - |
Interest Expenses | 6.4% | 80.00 | 76.00 | 67.00 | 57.00 | - |
Net Income | 2.4% | -484 | -496 | -517 | -616 | -586 |
Net Income Margin | 11.0% | -4.49* | -5.04* | -7.42* | - | - |
Free Cahsflow | 9.1% | -424 | -466 | -458 | -519 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 0.4% | 626 | 623 | 729 | 862 | 813 |
Current Assets | 0.7% | 553 | 549 | 642 | 771 | 716 |
Cash Equivalents | 8.1% | 407 | 377 | 483 | 470 | 372 |
Net PPE | -6.9% | 14.00 | 15.00 | 16.00 | 17.00 | 17.00 |
Liabilities | -1.5% | 1,839 | 1,868 | 1,859 | 1,877 | 1,854 |
Current Liabilities | -20.4% | 97.00 | 121 | 119 | 141 | 103 |
LT Debt, Non Current | 1.1% | 436 | 431 | 434 | - | - |
Shareholder's Equity | 2.4% | -1,213 | -1,243 | -1,041 | - | - |
Retained Earnings | -7.3% | -2,057 | -1,918 | -1,780 | -1,643 | -1,633 |
Additional Paid-In Capital | 17.9% | 1,107 | 939 | 917 | 893 | 868 |
Shares Outstanding | 6.5% | 160 | 151 | 149 | 148 | 148 |
Minority Interest | 8.6% | 12.00 | 11.00 | 10.00 | 12.00 | -0.03 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 3.9% | -403 | -419 | -460 | -446 | -507 |
Share Based Compensation | -2.4% | 89.00 | 92.00 | 90.00 | 88.00 | 90.00 |
Cashflow From Investing | -27.9% | 327 | 453 | 457 | 369 | 220 |
Cashflow From Financing | 1145.2% | 137 | -13.13 | 306 | 169 | 188 |
Buy Backs | - | 0.00 | - | - | - | - |
93.7%
88.9%
63.3%
Y-axis is the maximum loss one would have experienced if BridgeBio Pharma was unfortunately bought at previous high price.
-22.7%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -11.66 | 182,597 | 380,610 | -% |
2023-05-23 | Capital Impact Advisors, LLC | reduced | -15.31 | 209,764 | 458,702 | 0.56% |
2023-05-22 | PUTNAM INVESTMENTS LLC | added | 38.41 | 532,843 | 797,730 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -38.04 | 160,740 | 623,740 | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -36.43 | 1,546,000 | 5,577,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -23.07 | 371,000 | 922,000 | -% |
2023-05-16 | PERCEPTIVE ADVISORS LLC | added | 12.37 | 18,687,200 | 31,618,600 | 0.93% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 576 | 8,118,160 | 8,709,610 | -% |
2023-05-16 | JANE STREET GROUP, LLC | added | 196 | 2,241,080 | 2,653,000 | -% |
2023-05-16 | Rockefeller Capital Management L.P. | added | 8.57 | 470,000 | 815,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | kumar neil | 6.42% | 9,823,908 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 7.09% | 10,591,455 | SC 13G/A | |
Feb 08, 2023 | state street corp | 5.92% | 8,844,943 | SC 13G | |
Feb 01, 2023 | blackrock inc. | 6.6% | 9,834,401 | SC 13G/A | |
Feb 15, 2022 | perceptive advisors llc | 4.8% | 7,128,755 | SC 13G/A | |
Feb 14, 2022 | kumar neil | 6.05% | 9,003,211 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 6.34% | 9,331,683 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 6.3% | 9,275,590 | SC 13G/A | |
Feb 17, 2021 | kkr genetic disorder l.p. | 20.9% | 31,060,971 | SC 13D/A | |
Feb 16, 2021 | american international group, inc. | 2.8% | 3,381,412 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 18, 2023 | 4 | Insider Trading | |
May 18, 2023 | 4 | Insider Trading | |
May 18, 2023 | 4 | Insider Trading | |
May 17, 2023 | 144 | Notice of Insider Sale Intent | |
May 17, 2023 | 144 | Notice of Insider Sale Intent | |
May 05, 2023 | 4 | Insider Trading | |
May 05, 2023 | 4 | Insider Trading | |
May 04, 2023 | 10-Q | Quarterly Report | |
May 04, 2023 | S-8 | Employee Benefits Plan | |
May 04, 2023 | S-3ASR | S-3ASR |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-17 | Kumar Neil | sold | -722,218 | 14.0095 | -51,552 | ceo and president |
2023-05-17 | STEPHENSON BRIAN C | sold | -342,168 | 14.0095 | -24,424 | secretary, treasurer & cfo |
2023-05-16 | HOMCY CHARLES J | acquired | - | - | 3,759 | - |
2023-05-16 | Kumar Neil | acquired | - | - | 102,249 | ceo and president |
2023-05-16 | STEPHENSON BRIAN C | sold (taxes) | -289,859 | 14.09 | -20,572 | secretary, treasurer & cfo |
2023-05-16 | Kumar Neil | sold (taxes) | -714,321 | 14.09 | -50,697 | ceo and president |
2023-05-16 | STEPHENSON BRIAN C | acquired | - | - | 44,996 | secretary, treasurer & cfo |
2023-05-16 | HOMCY CHARLES J | sold (taxes) | -18,317 | 14.09 | -1,300 | - |
2023-05-03 | STEPHENSON BRIAN C | sold | -920,693 | 14.18 | -64,929 | secretary, treasurer & cfo |
2023-05-03 | Kumar Neil | sold | -1,701,740 | 14.1812 | -120,000 | ceo and president |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue: | ||
Total revenue | $ 1,826 | $ 1,694 |
Operating costs and expenses: | ||
Cost of license revenue and products sold | 651 | 1,348 |
Research and development | 92,861 | 107,649 |
Selling, general and administrative | 31,108 | 43,713 |
Restructuring, impairment and related charges | 3,369 | 22,662 |
Total operating costs and expenses | 127,989 | 175,372 |
Loss from operations | (126,163) | (173,678) |
Other income (expense), net: | ||
Interest income | 4,153 | 267 |
Interest expense | (20,121) | (20,344) |
Other expense, net | (601) | (7,575) |
Total other income (expense), net | (16,569) | (27,652) |
Net loss | (142,732) | (201,330) |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,576 | 4,933 |
Net loss attributable to common stockholders of BridgeBio | $ (140,156) | $ (196,397) |
Net loss per share attributable to common stockholders of BridgeBio, basic | $ (0.92) | $ (1.35) |
Net loss per share attributable to common stockholders of BridgeBio, diluted | $ (0.92) | $ (1.35) |
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic | 152,645,635 | 145,882,149 |
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted | 152,645,635 | 145,882,149 |
License and Services Revenue | ||
Revenue: | ||
Total revenue | $ 1,826 | $ 235 |
Product Sales | ||
Revenue: | ||
Total revenue | $ 1,459 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 | |||||
---|---|---|---|---|---|---|---|
Current assets: | |||||||
Cash and cash equivalents | $ 407,368 | $ 376,689 | [1] | ||||
Marketable securities | 34,122 | 51,580 | [1] | ||||
Investment in equity securities | 49,803 | 43,653 | [1] | ||||
Receivable from licensing and collaboration agreements | 10,761 | 17,079 | [1] | ||||
Restricted cash | 25,503 | 37,930 | [1] | ||||
Prepaid expenses and other current assets | 25,145 | 21,922 | [1] | ||||
Total current assets | 552,702 | 548,853 | [1] | ||||
Property and equipment, net | 13,566 | 14,569 | [1] | ||||
Operating lease right-of-use assets | 10,532 | 10,678 | [1] | ||||
Intangible assets, net | 28,113 | 28,712 | [1] | ||||
Other assets | 20,767 | 20,224 | [1] | ||||
Total assets | 625,680 | 623,036 | [1] | ||||
Current liabilities: | |||||||
Accounts payable | 4,076 | 11,558 | [1] | ||||
Accrued compensation and benefits | 18,869 | 31,256 | [1] | ||||
Accrued research and development liabilities | 37,064 | 39,803 | [1] | ||||
Accrued professional services | 4,015 | 1,790 | [1] | ||||
Operating lease liabilities, current portion | 3,674 | 3,675 | [1] | ||||
Deferred revenue, current portion | 6,675 | 8,156 | [1] | ||||
Other accrued liabilities | 22,223 | 25,190 | [1] | ||||
Total current liabilities | 96,596 | 121,428 | [1] | ||||
Term loan, net | 435,764 | 430,993 | [1] | ||||
Operating lease liabilities, net of current portion | 11,904 | 12,274 | [1] | ||||
Other long-term liabilities | 17,501 | 26,643 | [1] | ||||
Total liabilities | 1,839,293 | 1,867,960 | [1] | ||||
Commitments and contingencies (Note 8) | |||||||
Redeemable convertible noncontrolling interests | (204) | (1,589) | |||||
Stockholders’ equity (deficit): | |||||||
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | |||||||
Common stock, $0.001 par value; 500,000,000 shares authorized;166,626,999 shares issued and 160,435,238 shares outstanding as of March 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022 | 167 | 157 | [1] | ||||
Treasury stock, at cost; 6,191,761 shares as of March 31, 2023 and December 31, 2022 | (275,000) | (275,000) | [1] | ||||
Additional paid-in capital | 1,106,635 | 938,703 | [1] | ||||
Accumulated other comprehensive loss | (12) | (328) | [1] | ||||
Accumulated deficit | (2,057,455) | (1,918,149) | [1] | ||||
Total BridgeBio stockholders' deficit | (1,225,665) | (1,254,617) | [1] | ||||
Noncontrolling interests | 12,256 | 11,282 | [1] | ||||
Total stockholders' deficit | (1,213,409) | (1,243,335) | [1],[2] | ||||
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit | 625,680 | 623,036 | [1] | ||||
2029 Notes | |||||||
Current liabilities: | |||||||
Notes, net | 735,463 | 734,988 | [1] | ||||
2027 Notes | |||||||
Current liabilities: | |||||||
Notes, net | $ 542,065 | $ 541,634 | [1] | ||||
|